Kras

Detecting KRAS mutations in colorectal carcinoma patients with high resolution melting curve analysis

利用高分辨率熔解曲线分析法检测结直肠癌中KRAS基因突变

The two probes are able to detect KRAS genotype .

这2种探针都能够有效检测Kras的基因型。

KRAS Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

西妥昔单抗治疗进展性结直肠癌的疗效与KRAS基因突变状态的关系

Kras gene , one of the oncogens , is frequently mutated in tumors .

Kras基因是一种癌基因，在肿瘤中的突变率较高。

No mutation of p53 and Kras was detected both in benign pulmonary lesion tissues and sputum cells in patients with benign pulmonary diseases .

肺良性病变肺组织和肺良性疾病患者痰液脱落细胞中均未检测到p53和Kras基因突变。

The KRAS proto-oncogene product lies downstream of EGFR , and the mutation frees the receptor from normal regulation in cell-growth control .

原癌基因KRAS是表皮生长因子受体下游产物，它的突变使其不受在细胞生长控制中正常调节的受体影响。

The mutation rate of Kras gene was 23.7 % ( 14 / 59 ) and 20.3 % ( 12 / 59 ) in cancer tissues and sputum cells respectively .

肺癌组织和患者痰液脱落细胞中Kras基因突变率分别为23.7%（14/59）和20.3%（12/59）。

KRAS mutation frequency in tumor tissue , can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis , and molecular inhibitors of RAS genes is still in its infancy .

KRAS基因突变在恶性肿瘤组织中频发，可预测非小细胞肺癌分子靶向治疗的疗效和预后，针对RAS基因的分子抑制剂研究仍处于初级阶段。

Intracellular signaling pathway is cross linked with each other to form a complex signaling network . Specific inhibition of activated KRAS in PC may cause genetic changes that involve in changing expression of many genes , which could develop resistance to various treatments .

细胞内的信号通路互相交联构成复杂的通路网络，针对KRAS基因采用的治疗措施可能会导致与它相关联的基因发生改变，从而对治疗产生耐受。

The mutation rate ( 54.2 % ) of combination detection of p53 and Kras in sputum cells was significantly higher than that of p53 ( 33.9 % ) or Kras ( 20.3 % ) alone ( P < 0.05 ) .

联合检测肺癌患者痰液脱落细胞p53和Kras基因突变率为54.2%（32/59），显著高于痰脱落细胞中33.9%的p53突变和20.3%的Kras突变率。